Clinical Trials
Adjuvant Sacituzumab Govitecan & Pembrolizumab vs. SOC tx in patients with TNBC
Disease Type: Breast
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians' Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville